The phase 3 trial assessed Xtandi plus androgen deprivation therapy (ADT) against placebo plus ADT in men with non-metastatic castration-resistant prostate cancer (nmCRPC). The OS was a major
The post Pfizer, Astellas’ Xtandi significantly improves OS in phase 3 prostate cancer study appeared first on Pharmaceutical Business review.